Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

ACCD

Accolade Inc

Feb 04 • 04:00PM ET

6.91

Dollar change -0.03
Percentage change -0.43	%

Healthcare • Health Information Services • USA • NASD

Peers: HCA TDOC UHS HIMS AMWL PGNY SEM ACHC CHE CYRX

| Held by: ARKG IWM VTI VXF IWN SCHA DFAT IWO DFAS SMLF

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.25	Insider Own	14.29%	Shs Outstand	81.19M	Perf Week	0.44%
Market Cap	564.40M	Forward P/E	-	EPS next Y	-0.85	Insider Trans	-0.49%	Shs Float	70.00M	Perf Month	102.05%
Income	-180.30M	PEG	-	EPS next Q	0.05	Inst Own	78.51%	Short Float	4.76%	Perf Quarter	117.98%
Sales	446.72M	P/S	1.26	EPS this Y	-3.21%	Inst Trans	9.81%	Short Ratio	1.67	Perf Half Y	85.25%
Book/sh	3.86	P/B	1.79	EPS next Y	38.38%	ROA	-25.16%	Short Interest	3.33M	Perf Year	-41.09%
Cash/sh	2.76	P/C	2.50	EPS next 5Y	22.82%	ROE	-48.23%	52W Range	3.08 - 13.93	Perf YTD	102.05%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-2.85%	ROI	-33.17%	52W High	-50.39%	Beta	2.19
Dividend TTM	-	Quick Ratio	2.59	Sales past 5Y	36.31%	Gross Margin	38.44%	52W Low	124.35%	ATR (14)	0.16
Dividend Ex-Date	-	Current Ratio	2.59	EPS Y/Y TTM	-35.83%	Oper. Margin	-19.25%	RSI (14)	85.03	Volatility	0.68% 1.50%
Employees	2400	Debt/Eq	0.76	Sales Y/Y TTM	14.99%	Profit Margin	-40.36%	Recom	2.67	Target Price	7.31
Option/Short	Yes / Yes	LT Debt/Eq	0.74	EPS Q/Q	-443.60%	Payout	-	Rel Volume	1.05	Prev Close	6.94
Sales Surprise	-0.88%	EPS Surprise	-362.53%	Sales Q/Q	5.73%	Earnings	Jan 10 BMO	Avg Volume	2.00M	Price	6.91
SMA20	5.78%	SMA50	45.51%	SMA200	41.76%	Trades		Volume	2,087,209	Change	-0.43%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-28-24	Reiterated	Needham	Buy	$13 → $8
Feb-26-24	Initiated	Leerink Partners	Outperform	$16
Jan-17-24	Resumed	DA Davidson	Neutral	$16 → $14
Jan-03-24	Initiated	Barclays	Equal Weight	$13
May-24-23	Upgrade	BofA Securities	Neutral → Buy	$16.50
Apr-12-23	Initiated	Stephens	Overweight	$18
Mar-23-23	Upgrade	Guggenheim	Neutral → Buy	$16
Feb-09-23	Downgrade	Jefferies	Buy → Hold	$14
Feb-02-23	Initiated	Raymond James	Outperform	$15
Sep-08-22	Resumed	Piper Sandler	Overweight	$12
Sep-07-22	Initiated	Truist	Buy	$15
Aug-12-22	Initiated	DA Davidson	Buy	$16
May-02-22	Upgrade	Wells Fargo	Underweight → Equal Weight	$6
Apr-29-22	Downgrade	SVB Leerink	Outperform → Mkt Perform	$32 → $8
Apr-29-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$30 → $9
Apr-29-22	Downgrade	Credit Suisse	Outperform → Neutral	$33 → $9
Apr-29-22	Downgrade	BTIG Research	Buy → Neutral
Apr-29-22	Downgrade	BofA Securities	Buy → Neutral	$45 → $9
Apr-11-22	Initiated	Wells Fargo	Underweight	$9
Apr-07-22	Initiated	Guggenheim	Neutral

Show Previous Ratings

Feb-04-25 09:00AM	Accolade Expands Virtual Care to Medicare Beneficiaries Nationwide Through PlushCare Direct-to-Consumer Offering (PR Newswire)
Feb-03-25 07:31PM	Why Accolade Inc (ACCD) Is Skyrocketing So Far In 2025 (Insider Monkey)
Jan-24-25 03:58PM	Dell Technologies, Accolade, and More Stocks See Action From Activist Investors (Barrons.com)
03:58PM	Dell Technolodies, Accolade, and More Stocks See Action From Activist Investors (Barrons.com)
Jan-22-25 08:08AM	Is Accolade, Inc. (ACCD) the Hottest Smid-Cap Stock So Far In 2025? (Insider Monkey)
11:05AM	Loading…
Jan-10-25 11:05AM	Accolade (ACCD) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
10:03AM	Accolade: Fiscal Q3 Earnings Snapshot (Associated Press Finance)
Jan-09-25 10:17AM	Transcarent to acquire health advocacy and primary care company Accolade for $621m (Hospital Management)
08:35AM	Accolade to be acquired by Transcarent for $7.03 per share in cash (TipRanks)
Jan-08-25 08:30AM	Transcarent To Acquire Accolade (GlobeNewswire) +104.78%
07:03AM	Accolade Inc (ACCD) Q3 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
05:50AM	Transcarent to acquire fellow health benefits navigator Accolade for $621M (Healthcare Dive)
Dec-16-24 08:00AM	Accolade to Announce Fiscal Third Quarter 2025 Financial Results (GlobeNewswire)
Dec-03-24 12:00PM	Accolade (ACCD) Upgraded to Buy: Here's Why (Zacks) -5.80%
Nov-13-24 08:00AM	Accolade To Present at Upcoming Investor Conferences (GlobeNewswire)
09:35AM	Loading…
Oct-24-24 09:35AM	Accolade (ACCD) Loses -15.57% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Oct-15-24 09:00AM	Accolade Welcomes Renalogic to Trusted Partner Ecosystem (PR Newswire)
Oct-10-24 12:00PM	Accolade (ACCD) Upgraded to Buy: Here's What You Should Know (Zacks)
Oct-09-24 03:00AM	Accolade Inc (ACCD) Q2 2025 Earnings Call Transcript Highlights: Strong Revenue and Cash Flow ... (GuruFocus.com)
Oct-08-24 10:33PM	Q2 2025 Accolade Inc Earnings Call (Thomson Reuters StreetEvents)
08:47AM	Accolade's Q2 Boost: Revenue Rises, Losses Shrink, And Profitability Looms (Benzinga)
08:10AM	Accolade (ACCD) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:38AM	Accolade shares soar on narrower quarterly loss, margin growth (Investing.com)
07:08AM	Accolade: Fiscal Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Accolade Announces Results for Fiscal Second Quarter 2025 (GlobeNewswire)
Oct-07-24 09:01AM	Accolade Inc (ACCD) Q2 2025: Everything You Need to Know Ahead of Earnings (GuruFocus.com) +5.87%
Sep-18-24 08:00AM	Accolade to Announce Fiscal Second Quarter 2025 Financial Results (GlobeNewswire)
Sep-12-24 07:24AM	One of the largest blockchain fund of funds has raised over $135 million across two new vehicles (Fortune)
Aug-30-24 12:00PM	All You Need to Know About Accolade (ACCD) Rating Upgrade to Buy (Zacks)
Aug-28-24 08:00AM	Accolade To Present at Morgan Stanley 22nd Annual Global Healthcare Conference (GlobeNewswire)
10:03AM	Loading…
Aug-22-24 10:03AM	First-of-its-kind Healthcare Innovation Provides Synchronized, Customized Whole-Health Strategies (PR Newswire)
Aug-07-24 08:00AM	Accolade To Present at Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase (GlobeNewswire)
Jul-12-24 09:35AM	After Plunging -46.98% in 4 Weeks, Here's Why the Trend Might Reverse for Accolade (ACCD) (Zacks)
Jul-11-24 09:35AM	After Plunging -47.01% in 4 Weeks, Here's Why the Trend Might Reverse for Accolade (ACCD) (Zacks)
Jun-28-24 09:55AM	Accolade Stock on Pace for All-Time Low as Guidance Disappoints. The Case to Buy the Dip. (Barrons.com) -43.97%
08:04AM	Accolade Stock Sinks After Guidance Disappoints. The Case to Buy the Dip. (Barrons.com)
08:03AM	Accolade, Inc. (NASDAQ:ACCD) Q1 2025 Earnings Call Transcript (Insider Monkey)
07:58AM	Midday movers: Nike and Accolade fall; Humana and Infinera rise (Investing.com)
07:39AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace)
Jun-27-24 08:53PM	ACCD Stock Earnings: Accolade Beats EPS, Beats Revenue for Q1 2025 (InvestorPlace)
05:15PM	Accolade (ACCD) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:09PM	Accolade: Fiscal Q1 Earnings Snapshot (Associated Press Finance)
04:03PM	Accolade Announces Results for Fiscal First Quarter 2025 (GlobeNewswire)
08:59AM	Is Accolade Inc. (ACCD) a Good Small-Cap Stock to Buy? (Insider Monkey)
Jun-26-24 04:36PM	Top 10 Small-Cap Stocks with Highest Upside Potential (Insider Monkey)
Jun-14-24 06:55AM	Can Accolade (ACCD) Sustain an Annual Revenue Growth Rate of 20%? (Insider Monkey)
Jun-12-24 08:00AM	Accolade to Announce Fiscal First Quarter 2025 Financial Results (GlobeNewswire)
May-29-24 08:00AM	Accolade To Present at William Blair Growth Stock Conference (GlobeNewswire) -5.49%
May-21-24 09:00AM	Accolade Welcomes Noom to Trusted Partner Ecosystem (PR Newswire) -5.21%
May-10-24 11:45AM	Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought (Motley Fool)
Apr-30-24 11:04AM	Wells Fargo Cuts Price Target on Accolade to $10 From $12, Maintains Equalweight Rating (MT Newswires) -6.84%
08:45AM	Accolade, Inc. (NASDAQ:ACCD) Q4 2024 Earnings Call Transcript (Insider Monkey)
Apr-26-24 06:32PM	10 Cathie Wood Stocks Insiders are Selling (Insider Monkey) -14.15%
12:47PM	Morgan Stanley Trims Accolade's Price Target to $12 From $13, Maintains Equal Weight Rating (MT Newswires)
06:41AM	Q4 2024 Accolade Inc Earnings Call (Thomson Reuters StreetEvents)
03:38AM	Accolade Inc (ACCD) Q4 2024 Earnings Call Transcript Highlights: Record Revenue and Strategic ... (GuruFocus.com)
Apr-25-24 05:42PM	Accolade Inc (ACCD) Surpasses Revenue Expectations and Narrows Losses in Fiscal Q4 and Full ... (GuruFocus.com)
05:15PM	Accolade (ACCD) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:14PM	Accolade: Fiscal Q4 Earnings Snapshot (Associated Press Finance)
04:03PM	Accolade Announces Results for Fiscal Fourth Quarter and Full Year 2024 (GlobeNewswire)
Apr-03-24 08:00AM	Accolade to Announce Fiscal Fourth Quarter 2024 Financial Results (GlobeNewswire)
Mar-20-24 09:00AM	Accolade Wins 2024 Artificial Intelligence Excellence Award (PR Newswire)
Mar-19-24 09:00AM	Accolade Promotes Kelsi McDonald Harris to Chief People Officer (PR Newswire)
Feb-28-24 08:00AM	Accolade To Present at Upcoming Investor Conferences (GlobeNewswire)
Feb-27-24 09:00AM	Accolade Welcomes Brightline to Trusted Partner Ecosystem (PR Newswire)
Feb-23-24 05:15AM	20 Most Valuable Digital Health Companies In The US (Insider Monkey)
Feb-07-24 09:40AM	Are Business Services Stocks Lagging Accolade (ACCD) This Year? (Zacks)
Feb-05-24 09:55AM	Does Accolade (ACCD) Have the Potential to Rally 25.58% as Wall Street Analysts Expect? (Zacks)
Jan-23-24 09:00AM	Accolade Welcomes Kindbody to Trusted Partner Ecosystem (PR Newswire)
Jan-19-24 09:55AM	Wall Street Analysts Predict a 26.85% Upside in Accolade (ACCD): Here's What You Should Know (Zacks)
08:36AM	Why Accolade (ACCD) Stock Might be a Great Pick (Zacks)
Jan-11-24 09:03AM	Accolade, Inc. (NASDAQ:ACCD) Q3 2024 Earnings Call Transcript (Insider Monkey)
Jan-09-24 11:05AM	Q3 2024 Accolade Inc Earnings Call (Thomson Reuters StreetEvents) +29.00%
Jan-08-24 10:35PM	Accolade Inc (ACCD) Reports Revenue Growth and Shrinking Net Loss in Fiscal Q3 2024 (GuruFocus.com)
09:51PM	ACCD Stock Earnings: Accolade Beats EPS, Beats Revenue for Q3 2024 (InvestorPlace)
04:11PM	Accolade: Fiscal Q3 Earnings Snapshot (Associated Press Finance)
04:03PM	Accolade Announces Results for Fiscal Third Quarter 2024 (GlobeNewswire)
Jan-02-24 08:00AM	Accolade To Present at Upcoming Investor Conferences (GlobeNewswire)
Jan-01-24 10:00AM	Will Accolade (ACCD) Report Negative Earnings Next Week? What You Should Know (Zacks)
Dec-11-23 08:00AM	Accolade to Announce Fiscal Third Quarter 2024 Financial Results (GlobeNewswire)
Dec-05-23 09:40AM	Is Accolade (ACCD) Stock Outpacing Its Business Services Peers This Year? (Zacks)
Nov-27-23 08:00AM	Accolade To Present at Piper Sandler 35th Annual Healthcare Conference (GlobeNewswire)
Nov-16-23 04:03PM	Accolade Announces Repurchase of $76.5 Million of 0.50% Convertible Senior Notes Due 2026 (GlobeNewswire) +5.91%
Nov-08-23 03:00PM	Accolade To Present at Stephens Annual Investment Conference (GlobeNewswire)
11:11AM	Accolade Named to 2023 Deloitte Technology Fast 500 (PR Newswire)
Nov-02-23 09:35AM	Down -31.39% in 4 Weeks, Here's Why Accolade (ACCD) Looks Ripe for a Turnaround (Zacks)
Oct-09-23 09:35AM	Here's Why Accolade (ACCD) is Poised for a Turnaround After Losing -36.43% in 4 Weeks (Zacks)
09:00AM	GLP-1 Coverage in Employer Plans Could Nearly Double in 2024 (PR Newswire)
Oct-06-23 11:31AM	Why Shares of Accolade Fell This Week (Motley Fool)
Oct-05-23 08:21AM	Accolade, Inc. (NASDAQ:ACCD) Q2 2024 Earnings Call Transcript (Insider Monkey) -13.13%
06:50AM	Q2 2024 Accolade Inc Earnings Call (Thomson Reuters StreetEvents)
Oct-04-23 05:43PM	Accolade Inc (ACCD) Reports Strong Q2 2024 Earnings, Exceeds Top and Bottom Line Guidance (GuruFocus.com)
05:25PM	Accolade (ACCD) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:15PM	Accolade: Fiscal Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Accolade Announces Results for Fiscal Second Quarter 2024 (GlobeNewswire)
Sep-20-23 08:00AM	Accolade to Announce Fiscal Second Quarter 2024 Financial Results (GlobeNewswire)
Sep-18-23 09:00AM	Accolade Expands Physician-Executive Leadership to Enhance Care Delivery and Improve the Healthcare Experience (PR Newswire)
Sep-13-23 09:09PM	Insider Sell: Accolade Inc President Robert Cavanaugh Sells 215 Shares (GuruFocus.com)
Sep-06-23 02:08PM	CORRECTING and REPLACING -- Accolade To Present at Upcoming Investor Conferences (GlobeNewswire)
Sep-05-23 08:00AM	Accolade To Present at Upcoming Investor Conferences (GlobeNewswire)

Accolade, Inc. engages in the provision of technology-enabled health and benefits solutions. The company was founded by Thomas K. Spann and J. Michael Cline in January 2007 and is headquartered in Seattle, WA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SINGH RAJEEV	Officer	Feb 04 '25	Proposed Sale	6.93	1,170	8,103		Feb 04 03:25 PM
Barnes Stephen H.	Officer	Feb 04 '25	Proposed Sale	6.93	448	3,103		Feb 04 03:21 PM
Cavanaugh Robert N	Officer	Feb 04 '25	Proposed Sale	6.93	557	3,858		Feb 04 03:20 PM
McHugh Colin	Officer	Feb 04 '25	Proposed Sale	6.93	506	3,504		Feb 04 03:19 PM
Eskew Richard	Officer	Feb 04 '25	Proposed Sale	6.93	390	2,701		Feb 04 03:17 PM
Kent Cindy	Director	Jan 30 '25	Option Exercise	0.00	1,406	0	10,602	Feb 03 11:52 AM
Barnes Stephen H.	Chief Financial Officer	Jan 17 '25	Option Exercise	4.20	78,000	327,600	300,244	Jan 22 04:12 PM
Cavanaugh Robert N	President	Jan 16 '25	Option Exercise	0.00	510	0	215,275	Jan 21 10:09 AM
Cavanaugh Robert N	President	Jan 17 '25	Sale	6.86	186	1,276	215,089	Jan 21 10:09 AM
SINGH RAJEEV	Chief Executive Officer	Jan 16 '25	Option Exercise	0.00	932	0	820,520	Jan 21 10:08 AM
SINGH RAJEEV	Chief Executive Officer	Jan 17 '25	Sale	6.86	309	2,119	820,211	Jan 21 10:08 AM
Barnes Stephen H.	Chief Financial Officer	Jan 16 '25	Option Exercise	0.00	415	0	222,398	Jan 21 10:05 AM
Barnes Stephen H.	Chief Financial Officer	Jan 17 '25	Sale	6.86	154	1,056	222,244	Jan 21 10:05 AM
Barnes Stephen H.	Officer	Jan 17 '25	Proposed Sale	6.86	154	1,056		Jan 17 03:17 PM
SINGH RAJEEV	Officer	Jan 17 '25	Proposed Sale	6.86	309	2,119		Jan 17 03:13 PM
Cavanaugh Robert N	Officer	Jan 17 '25	Proposed Sale	6.86	186	1,276		Jan 17 03:12 PM
Barnes Stephen H.	Chief Financial Officer	Jan 10 '25	Option Exercise	0.00	770	0	222,267	Jan 14 12:21 PM
Barnes Stephen H.	Chief Financial Officer	Jan 13 '25	Sale	6.88	284	1,954	221,983	Jan 14 12:21 PM
Cavanaugh Robert N	President	Jan 10 '25	Option Exercise	0.00	710	0	215,021	Jan 14 12:20 PM
Cavanaugh Robert N	President	Jan 13 '25	Sale	6.88	256	1,761	214,765	Jan 14 12:20 PM
SINGH RAJEEV	Chief Executive Officer	Jan 10 '25	Option Exercise	0.00	1,650	0	820,129	Jan 14 12:04 PM
SINGH RAJEEV	Chief Executive Officer	Jan 13 '25	Sale	6.88	541	3,722	819,588	Jan 14 12:04 PM
Barnes Stephen H.	Officer	Jan 13 '25	Proposed Sale	6.88	284	1,954		Jan 13 03:13 PM
Cavanaugh Robert N	Officer	Jan 13 '25	Proposed Sale	6.88	256	1,761		Jan 13 03:13 PM
SINGH RAJEEV	Officer	Jan 13 '25	Proposed Sale	6.88	541	3,721		Jan 13 03:12 PM
McHugh Colin	Chief Accounting Officer	Jan 02 '25	Option Exercise	0.00	1,534	0	62,590	Jan 06 04:26 PM
McHugh Colin	Chief Accounting Officer	Jan 03 '25	Sale	3.41	524	1,785	62,066	Jan 06 04:26 PM
Cavanaugh Robert N	President	Jan 02 '25	Option Exercise	0.00	1,569	0	214,864	Jan 06 04:25 PM
Cavanaugh Robert N	President	Jan 03 '25	Sale	3.41	553	1,884	214,311	Jan 06 04:25 PM
SINGH RAJEEV	Chief Executive Officer	Jan 02 '25	Option Exercise	0.00	3,786	0	819,637	Jan 06 04:22 PM
SINGH RAJEEV	Chief Executive Officer	Jan 03 '25	Sale	3.41	1,158	3,945	818,479	Jan 06 04:22 PM
Barnes Stephen H.	Chief Financial Officer	Jan 02 '25	Option Exercise	0.00	1,569	0	222,032	Jan 06 04:20 PM
Barnes Stephen H.	Chief Financial Officer	Jan 03 '25	Sale	3.41	535	1,823	221,497	Jan 06 04:20 PM
Eskew Richard	EVP General Counsel	Jan 02 '25	Option Exercise	0.00	1,146	0	63,653	Jan 06 04:19 PM
Eskew Richard	EVP General Counsel	Jan 03 '25	Sale	3.41	393	1,339	63,260	Jan 06 04:19 PM
SINGH RAJEEV	Officer	Jan 03 '25	Proposed Sale	3.41	1,158	3,946		Jan 03 04:36 PM
McHugh Colin	Officer	Jan 03 '25	Proposed Sale	3.41	524	1,785		Jan 03 04:20 PM
Barnes Stephen H.	Officer	Jan 03 '25	Proposed Sale	3.41	535	1,823		Jan 03 04:08 PM
Eskew Richard	Officer	Jan 03 '25	Proposed Sale	3.41	393	1,339		Jan 03 04:04 PM
Cavanaugh Robert N	Officer	Jan 03 '25	Proposed Sale	3.41	553	1,884		Jan 03 03:58 PM
Barnes Stephen H.	Chief Financial Officer	Dec 16 '24	Option Exercise	0.00	415	0	220,586	Dec 18 04:21 PM
Barnes Stephen H.	Chief Financial Officer	Dec 17 '24	Sale	3.43	123	422	220,463	Dec 18 04:21 PM
Cavanaugh Robert N	President	Dec 16 '24	Option Exercise	0.00	510	0	213,451	Dec 18 04:19 PM
Cavanaugh Robert N	President	Dec 17 '24	Sale	3.43	156	535	213,295	Dec 18 04:19 PM
SINGH RAJEEV	Chief Executive Officer	Dec 16 '24	Option Exercise	0.00	933	0	816,232	Dec 18 03:44 PM
SINGH RAJEEV	Chief Executive Officer	Dec 17 '24	Sale	3.43	381	1,308	815,851	Dec 18 03:44 PM
HILTON MICHAEL W	Director	Dec 16 '24	Option Exercise	0.00	332	0	150,946	Dec 18 03:42 PM
Barnes Stephen H.	Officer	Dec 17 '24	Proposed Sale	3.43	123	422		Dec 17 03:24 PM
Cavanaugh Robert N	Officer	Dec 17 '24	Proposed Sale	3.43	156	535		Dec 17 03:22 PM
SINGH RAJEEV	Officer	Dec 17 '24	Proposed Sale	3.43	381	1,308		Dec 17 03:18 PM
Cavanaugh Robert N	President	Dec 10 '24	Option Exercise	0.00	710	0	213,155	Dec 12 02:40 PM
Cavanaugh Robert N	President	Dec 11 '24	Sale	3.62	214	775	212,941	Dec 12 02:40 PM
Barnes Stephen H.	Chief Financial Officer	Dec 10 '24	Option Exercise	0.00	770	0	220,393	Dec 12 02:38 PM
Barnes Stephen H.	Chief Financial Officer	Dec 11 '24	Sale	3.62	222	804	220,171	Dec 12 02:38 PM
HILTON MICHAEL W	Director	Dec 10 '24	Option Exercise	0.00	184	0	150,614	Dec 12 02:36 PM
SINGH RAJEEV	Chief Executive Officer	Dec 10 '24	Option Exercise	0.00	1,650	0	815,966	Dec 12 02:30 PM
SINGH RAJEEV	Chief Executive Officer	Dec 11 '24	Sale	3.62	667	2,416	815,299	Dec 12 02:30 PM
Barnes Stephen H.	Officer	Dec 11 '24	Proposed Sale	3.62	222	804		Dec 11 03:33 PM
SINGH RAJEEV	Officer	Dec 11 '24	Proposed Sale	3.62	667	2,416		Dec 11 03:10 PM
Cavanaugh Robert N	Officer	Dec 11 '24	Proposed Sale	3.62	214	775		Dec 11 03:07 PM
SINGH RAJEEV	Chief Executive Officer	Dec 02 '24	Option Exercise	0.00	31,564	0	827,673	Dec 04 01:44 PM
SINGH RAJEEV	Chief Executive Officer	Dec 03 '24	Sale	3.60	13,357	48,018	814,316	Dec 04 01:44 PM
Cavanaugh Robert N	President	Dec 02 '24	Option Exercise	0.00	17,797	0	218,027	Dec 04 01:43 PM
Cavanaugh Robert N	President	Dec 03 '24	Sale	3.60	5,582	20,067	212,445	Dec 04 01:43 PM
Eskew Richard	EVP General Counsel	Dec 02 '24	Option Exercise	0.00	11,841	0	66,088	Dec 04 01:41 PM
Eskew Richard	EVP General Counsel	Dec 03 '24	Sale	3.60	3,581	12,874	62,507	Dec 04 01:41 PM
Barnes Stephen H.	Chief Financial Officer	Dec 02 '24	Option Exercise	0.00	18,679	0	225,263	Dec 04 01:33 PM
Barnes Stephen H.	Chief Financial Officer	Dec 03 '24	Sale	3.60	5,640	20,276	219,623	Dec 04 01:33 PM
McHugh Colin	Chief Accounting Officer	Dec 02 '24	Option Exercise	0.00	7,916	0	63,444	Dec 04 01:02 PM
McHugh Colin	Chief Accounting Officer	Dec 03 '24	Sale	3.60	2,388	8,585	61,056	Dec 04 01:02 PM
NABEL ELIZABETH G	Director	Dec 02 '24	Option Exercise	0.00	2,179	0	39,804	Dec 04 11:00 AM
BRODSKY JEFFREY S	Director	Dec 02 '24	Option Exercise	0.00	2,179	0	44,632	Dec 04 10:58 AM
Barnes Stephen H.	Officer	Dec 03 '24	Proposed Sale	3.59	5,640	20,275		Dec 03 03:54 PM
SINGH RAJEEV	Officer	Dec 03 '24	Proposed Sale	3.59	13,357	48,017		Dec 03 03:44 PM
McHugh Colin	Officer	Dec 03 '24	Proposed Sale	3.59	2,388	8,585		Dec 03 03:44 PM
Cavanaugh Robert N	Officer	Dec 03 '24	Proposed Sale	3.59	5,582	20,067		Dec 03 03:33 PM
Eskew Richard	Officer	Dec 03 '24	Proposed Sale	3.59	3,581	12,873		Dec 03 03:18 PM
SINGH RAJEEV	Chief Executive Officer	Nov 18 '24	Option Exercise	0.00	933	0	796,489	Nov 20 03:22 PM
SINGH RAJEEV	Chief Executive Officer	Nov 19 '24	Sale	3.35	380	1,271	796,109	Nov 20 03:22 PM
Cavanaugh Robert N	President	Nov 18 '24	Option Exercise	0.00	510	0	199,656	Nov 20 03:20 PM
Cavanaugh Robert N	President	Nov 19 '24	Sale	3.35	154	515	199,502	Nov 20 03:20 PM
Barnes Stephen H.	Chief Financial Officer	Nov 18 '24	Option Exercise	0.00	414	0	205,413	Nov 20 03:18 PM
Barnes Stephen H.	Chief Financial Officer	Nov 19 '24	Sale	3.35	121	405	205,292	Nov 20 03:18 PM
HILTON MICHAEL W	Director	Nov 18 '24	Option Exercise	0.00	332	0	150,430	Nov 20 03:16 PM
Cavanaugh Robert N	Officer	Nov 19 '24	Proposed Sale	3.34	154	515		Nov 19 03:26 PM
SINGH RAJEEV	Officer	Nov 19 '24	Proposed Sale	3.34	380	1,271		Nov 19 03:16 PM
Barnes Stephen H.	Officer	Nov 19 '24	Proposed Sale	3.34	121	405		Nov 19 03:15 PM
SINGH RAJEEV	Chief Executive Officer	Nov 11 '24	Option Exercise	0.00	1,650	0	796,224	Nov 13 11:21 AM
SINGH RAJEEV	Chief Executive Officer	Nov 12 '24	Sale	3.64	668	2,430	795,556	Nov 13 11:21 AM
Barnes Stephen H.	Chief Financial Officer	Nov 11 '24	Option Exercise	0.00	770	0	205,222	Nov 13 11:19 AM
Barnes Stephen H.	Chief Financial Officer	Nov 12 '24	Sale	3.64	223	811	204,999	Nov 13 11:19 AM
Cavanaugh Robert N	President	Nov 11 '24	Option Exercise	0.00	711	0	199,360	Nov 13 11:17 AM
Cavanaugh Robert N	President	Nov 12 '24	Sale	3.64	214	779	199,146	Nov 13 11:17 AM
HILTON MICHAEL W	Director	Nov 11 '24	Option Exercise	0.00	183	0	150,098	Nov 13 11:11 AM
Barnes Stephen H.	Officer	Nov 12 '24	Proposed Sale	3.64	223	811		Nov 12 03:29 PM
SINGH RAJEEV	Officer	Nov 12 '24	Proposed Sale	3.64	668	2,430		Nov 12 03:15 PM
Cavanaugh Robert N	Officer	Nov 12 '24	Proposed Sale	3.64	214	779		Nov 12 03:11 PM
Barnes Stephen H.	Chief Financial Officer	Nov 04 '24	Sale	3.15	458	1,442	204,452	Nov 05 10:56 AM
Cavanaugh Robert N	President	Nov 04 '24	Sale	3.15	475	1,496	198,649	Nov 05 10:54 AM
SINGH RAJEEV	Chief Executive Officer	Nov 04 '24	Sale	3.15	1,545	4,865	794,574	Nov 05 10:51 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ACCD

Accolade Inc

Upgrade your FINVIZ experience